Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion type Assertion NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_head.
- NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion description "[ These results suggest that, in a European-American population, ELAC2 217L and RNASEL 541E are associated with metastatic sporadic disease. ELAC2 and RNASEL SNP analysis may prove useful in determining which patients are at risk for developing clinically significant prostate carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_provenance.
- NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion evidence source_evidence_literature NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_provenance.
- NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion SIO_000772 16114055 NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_provenance.
- NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion wasDerivedFrom gad-20130706 NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_provenance.
- NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_assertion wasGeneratedBy ECO_0000203 NP45135.RAlVidoMI7s95XC-WA6b39UVG8UBp4CBLmCV3H_XeBPwo130_provenance.